Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Prostate Cancer

Part of paid clinical trials in Irvine, California.

Sponsor
City of Hope Medical Center
Study ID
NCT07769372
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Stage I Prostate Cancer AJCC v8
  • Stage II Prostate Cancer AJCC v8
  • Stage IIIA Prostate Cancer AJCC v8
  • Stage IIIB Prostate Cancer AJCC v8
  • Stage IVA Prostate Cancer AJCC v8

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Biopsy Procedure — PROCEDURE
    Undergo biopsy
  • Computed Tomography — PROCEDURE
    Undergo CT
  • Electronic Health Record Review — OTHER
    Ancillary studies
  • Magnetic Resonance Imaging — PROCEDURE
    Undergo MRI
  • MRI-guided Stereotactic Body Radiation Therapy — RADIATION
    Undergo MR-guided SBRT
  • Questionnaire Administration — OTHER
    Ancillary studies

Study Details

This clinical trial studies the side effects and how well magnetic resonance (MR)-guided stereotactic body radiation therapy (SBRT) works in treating patients with prostate cancer. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. MR-guided SBRT uses magnetic resonance imaging (MRI) to define and localize the area to be treated, which may help provide more accurate delivery of SBRT and lower side effects. MR-guided SBRT may be safe, tolerable, and/or effective in treating patients with prostate cancer.

Key Dates

First listed
Aug 17, 2026
Start date
Jan 1, 2027
Status verified
Aug 2026
Primary completion
Mar 9, 2029
Completion
Mar 9, 2029

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (MR-guided SBRT)
    Patients undergo five treatment fractions of MR-guided SBRT over 30-45 minutes each up to TIW over approximately 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI and biopsy throughout the study as well as CT on study.

Primary Outcome Measure

Incidence of grade ≥ 3 treatment-related toxicity [ Time Frame: Up to 90 days post-treatment ]

Locations (1)

FacilityCityStateZIPSite coordinators
City of Hope at Irvine LennarIrvineCalifornia92618
Julius Weng (PRINCIPAL_INVESTIGATOR)

Find similar trials in Irvine, CA

By research site
City of Hope at Irvine Lennar· Irvine, CA

Related Studies